SCHEMBL17200765

SCHEMBL17200765

O=C(O)CCCCCCCC(=O)Oc1cccc(O)c1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.51
CNR2 P34972 2/20 0.48
CNR1 P21554 2/20 0.48
PRSS1 P07477 1/20 0.48
PRSS2 P07478 1/20 0.48
PRSS3 P35030 1/20 0.48
ESR1 P03372 2/20 0.43
ESR2 Q92731 2/20 0.43
POLB P06746 1/20 0.43
VCAM1 P19320 1/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPK1 P28482 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
ALB P02768 1/20 0.43
MAPT P10636 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3166149 1.00 CYP3A4 (0.51) CYP3A4CNR2CNR1PRSS1PRSS2
SCHEMBL27705782 0.98 CYP3A4 (0.53) CYP3A4CNR2CNR1PRSS1PRSS2
SCHEMBL2845775 0.95 CYP3A4 (0.53) CYP3A4CNR2CNR1PRSS1PRSS2
SCHEMBL927349 0.94 CYP3A4 (0.46) CYP3A4CNR2CNR1PRSS1PRSS2
SCHEMBL927430 0.94 CYP3A4 (0.46) CYP3A4CNR2CNR1PRSS1PRSS2
SCHEMBL688275 0.94 CYP3A4 (0.58) CYP3A4CNR2CNR1PRSS1PRSS2
SCHEMBL689630 0.94 CYP3A4 (0.58) CYP3A4CNR2CNR1PRSS1PRSS2
SCHEMBL809344 0.94 CYP3A4 (0.58) CYP3A4CNR2CNR1PRSS1PRSS2
SCHEMBL928867 0.93 CYP3A4 (0.47) CYP3A4CNR2CNR1PRSS1PRSS2
SCHEMBL689823 0.92 CYP3A4 (0.59) CYP3A4CNR2CNR1PRSS1PRSS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3134062-B1 COSMETIC COMPOSITIONS HAVING REDUCED IRRITATION PROCTER & GAMBLE (US) 2019-09-04 EP disclosed
EP-3134062-A1 COSMETIC COMPOSITIONS HAVING REDUCED IRRITATION The Procter & Gamble Company (US) 2017-03-01 EP disclosed
US-9480634-B2 Cosmetic compositions THE PROCTER & GAMBLE COMPANY (US) 2016-11-01 US disclosed
WO-2015164290-A1 COSMETIC COMPOSITIONS HAVING REDUCED IRRITATION THE PROCTER & GAMBLE COMPANY (US) 2015-10-29 WO disclosed
US-20150305994-A1 Cosmetic Compositions THE PROCTER & GAMBLE COMPANY 2015-10-29 US disclosed
CN-101076457-B Pneumatic tire BRIDGESTONE CORP 2011-07-27 CN disclosed
CN-101076457-A Pneumatic tire BRIDGESTONE CORP (JP) 2007-11-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150305994-A1 Cosmetic Compositions FHIT, UGCG, TYR CYP3A4 1529/4885CNR2 633/4885CNR1 469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.